Canada’s Cannabis Experiment: “Chaos and Carnage” Five Years On
“Canada now has one of the highest youth cannabis rates in the World.” “Experts say it’s time Canadian Government treat cannabis more like tobacco!”
This damning assessment comes five years after Canada became the first nation to fully legalise recreational cannabis, promising a regulated market that would protect public health whilst generating revenue.
The reality has been far more troubling. What proponents heralded as a progressive policy experiment has instead become a cautionary tale of unintended consequences, with mounting evidence that advocates severely underestimated cannabis legalisation health risks when they either failed to anticipate or chose to ignore these significant public health harms.
The Buried Impact: A Public Health Crisis Emerges
Recent research reveals the extent to which cannabis legalisation has created serious health challenges that extend far beyond the rosy predictions of policy advocates. The evidence shows alarming increases in cannabis use disorder (CUD) and cannabis poisoning as cannabis legalisation health risks, particularly in states where authorities have legalised medical and recreational cannabis.
The statistics are sobering. States with medical cannabis laws experienced a staggering 42.7% increase in CUD and an even more alarming 88.6% rise in cannabis poisoning cases. Similarly, recreational cannabis laws contributed to a 31.6% spike in poisonings.
These figures highlight a worrying trend that challenges the fundamental assumptions underlying legalisation policies. Rather than creating safer patterns of use through regulation, legalisation actively drives increased problematic use and acute medical emergencies.
The Schizophrenia Crisis: JAMA’s Devastating Findings
The most alarming evidence comes from a landmark study published in JAMA Network Open, which tracked over 13.5 million individuals in Ontario from 2006 to 2022. The research reveals a staggering increase in the association between cannabis use disorder and schizophrenia during the period of cannabis policy liberalisation.
The study found that the population-attributable risk fraction for cannabis use disorder associated with schizophrenia increased from 3.7% in the pre-legalisation period to 10.3% during the post-legalisation period, nearly a threefold increase. Put simply, the proportion of new schizophrenia cases that could potentially have been prevented by eliminating severe cannabis use patterns almost tripled.
The Demographics of Devastation
The impact has been particularly severe amongst young people, with the highest risk occurring in adolescents and young adults. By the end of the study period, amongst males aged 19-24 years, cannabis use disorder accounts for an estimated 18.9% of incident schizophrenia cases.
The study also documented that the annual age-standardised incidence rate of cannabis use disorder increased by a staggering 497% between 2006 and 2022, whilst the incidence of psychosis not otherwise specified increased by 83.7% over the same period.
Perhaps most concerning is that over 70% of legal dried cannabis sold in Ontario now exceeds 20% THC content, more than doubling in potency since the study period began.
Global Cannabis Use: The Legalisation Effect
International data provides further evidence of the relationship between liberal cannabis policies and increased usage rates. Research shows that 12% of people use cannabis in countries where it is legalised, compared to just 5.4% in countries where it remains illegal.
Canada, with 27% as of 2023, now ranks second globally in cannabis use rates. They’re followed closely by Canada, with 27% as of 2023, and the island nation of Palau, with 24.2% as of 2007. The United States comes in fourth place, with more than one in five Americans (21.9%) using pot in the year 2020.
This pattern strongly suggests that legalisation policies are indeed driving increased population-level consumption, contrary to early arguments that legal availability would not significantly alter usage patterns.
Healthcare System Strain and Hidden Costs
The rise in CUD and cannabis poisoning has serious implications for healthcare systems. Communities with legal cannabis have seen a significant strain on their medical resources, driven by the costs and demand for treatments linked to cannabis-related health issues. From emergency visits caused by poisoning to longer-term care for CUD, the effects ripple outward, burdening not just healthcare providers but families and society at large.
These costs represent a hidden burden of legalisation that was rarely factored into initial cost-benefit analyses. The economic arguments for legalisation focused primarily on tax revenue and reduced enforcement costs, whilst largely ignoring the potential healthcare expenditure increases.
Vulnerable Populations: Women and Middle-Aged Adults
The research reveals that the impact of legalisation affects different populations unequally. Women and individuals aged 35 to 44 show particularly high vulnerability, displaying higher rates of cannabis addiction compared to other groups.
This demographic pattern contradicts early assumptions about who legalisation would most affect, revealing that legalisation’s harms extend well beyond stereotypical user groups.
The Normalisation Trap
While proponents often celebrate cannabis legalisation for its economic and medicinal benefits, these findings underline the often-overlooked cannabis legalisation health risks. Increased access to cannabis can lead to normalised use, inadvertently fuelling addiction and public health crises.
The regulatory frameworks put in place have proven inadequate to prevent significant increases in problematic use patterns, despite legalisation creating a false sense of safety around cannabis use.
International Implications: A Global Warning
The consistent patterns observed across different jurisdictions that have legalised cannabis suggest that cannabis legalisation health risks are not unique to Canada or specific to particular policy frameworks. The evidence indicates that legalisation itself, regardless of the specific regulatory approach, appears to be associated with increased cannabis use disorders and related health harms.
The prevalence of cannabis use varied between 0.42% and 43.90% across 33 European countries, 1.40% to 38.12% across 15 North and South American countries, 0.30% to 19.10% across 16 Asian countries, and 1.30% to 48.70% across 18 Oceania and African countries. This variation correlates strongly with the liberality of cannabis policies in different regions.
The Policy Response: Too Little, Too Late?
The findings call for a renewed focus on public health and safety when it comes to drug policy. With evidence pointing to the harmful impacts of cannabis legalisation (including spikes in CUD and poisoning) it is clear that safeguards must be prioritised. Education, awareness, and careful review of existing policies are essential to curb the unintended consequences and ensure that communities remain healthy and safe.
However, the question remains whether adequate safeguards are achievable once the genie of legalisation has been released from the bottle. The Canadian experience, designed as a model of responsible legalisation, still resulted in dramatic increases in cannabis-related health problems.
A Sobering Assessment
The accumulating evidence from cannabis legalisation experiments presents a sobering picture that challenges many of the assumptions underlying these policies. The promise of well-regulated markets protecting public health whilst generating revenue has not materialised as expected.
Instead, we see consistent patterns of increased cannabis use disorders, emergency department visits for cannabis-related problems, and concerning associations with serious mental health conditions like schizophrenia. These harms appear particularly concentrated amongst young people and other vulnerable populations.
By closely monitoring the consequences of cannabis legalisation and pushing for proactive measures, we can better protect society against the risks tied to this controversial substance.
The question now facing policymakers is whether the benefits of legalisation (reduced incarceration, tax revenue, and regulated product quality) justify these documented public health costs. The evidence suggests that current approaches to cannabis legalisation may require fundamental reconsideration to adequately protect public health.
For jurisdictions contemplating legalisation, the experiences of early adopters provide crucial data that should inform more cautious and health-protective approaches to cannabis policy. Policymakers must understand cannabis legalisation health risks because young people face particular vulnerability to cannabis-related harms, and long-term consequences may not become fully apparent for years to come.
Source:
Leave a Reply